El año pasado, Baxter International Inc generó 4.10B USD en su segmento con mejor rendimiento, Infusion Therapies and Technologies. United States realizó la mayor aportación, representando 6.12B USD el año pasado. Para el último trimestre, Baxter International Inc reportó unos ingresos de 1.75B USD para el periodo finalizado el 2026-06-30, procedentes del segmento con mejor rendimiento, Infusion Therapies and Technologies. United States aportó los mayores ingresos, alcanzando los 1.59B USD.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Infusion Therapies and Technologies

Care and Connectivity Solutions

Injectables and Anesthesia

Advanced Surgery

Front Line Care

Drug Compounding

Other

Chronic Therapies

Acute Therapies

Renal Care

Medication Delivery

Pharmaceuticals

Patient Support Systems

Clinical Nutrition

Acute Theapies

BioPharma Solutions

Surgical Solutions

Other Product Or Services

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Infusion Therapies and Technologies

4.10B(36.47%)

4.10B(38.58%)

3.96B(26.73%)

3.82B(13.89%)

3.84B(16.10%)

--(--)

Care and Connectivity Solutions

1.91B(17.00%)

1.81B(17.06%)

1.80B(12.15%)

1.79B(6.52%)

142.00M(0.59%)

--(--)

Injectables and Anesthesia

1.35B(12.02%)

1.37B(12.91%)

1.35B(9.09%)

1.30B(4.75%)

1.39B(5.82%)

--(--)

Advanced Surgery

1.20B(10.65%)

1.10B(10.38%)

1.05B(7.10%)

998.00M(3.63%)

977.00M(4.09%)

888.00M(7.61%)

877.00M(7.72%)

800.00M(7.19%)

Front Line Care

1.16B(10.32%)

1.14B(10.69%)

1.21B(8.19%)

1.15B(4.18%)

70.00M(0.29%)

--(--)

Drug Compounding

1.14B(10.15%)

1.04B(9.76%)

902.00M(6.09%)

821.00M(2.99%)

901.00M(3.77%)

--(--)

Other

381.00M(3.39%)

67.00M(0.63%)

87.00M(0.59%)

177.00M(0.64%)

140.00M(0.59%)

--(--)

Chronic Therapies

--(--)

3.68B(24.86%)

3.71B(13.52%)

3.86B(16.17%)

--(--)

Acute Therapies

--(--)

770.00M(5.20%)

735.00M(2.68%)

820.00M(3.43%)

--(--)

Renal Care

--(--)

3.75B(13.64%)

3.90B(16.33%)

3.76B(32.19%)

3.64B(32.03%)

3.66B(32.91%)

Medication Delivery

--(--)

2.89B(10.50%)

2.88B(12.06%)

2.73B(23.43%)

2.80B(24.63%)

2.67B(23.99%)

Pharmaceuticals

--(--)

2.13B(7.74%)

2.29B(9.59%)

2.12B(18.19%)

2.15B(18.97%)

2.09B(18.80%)

Patient Support Systems

--(--)

1.49B(5.41%)

115.00M(0.48%)

--(--)

Clinical Nutrition

--(--)

931.00M(3.39%)

964.00M(4.04%)

922.00M(7.90%)

872.00M(7.67%)

877.00M(7.88%)

Acute Theapies

--(--)

701.00M(2.55%)

782.00M(3.27%)

740.00M(6.34%)

535.00M(4.71%)

517.00M(4.65%)

BioPharma Solutions

--(--)

644.00M(2.34%)

669.00M(2.80%)

--(--)

Surgical Solutions

--(--)

304.00M(1.11%)

27.00M(0.11%)

--(--)

Other Product Or Services

--(--)

140.00M(0.51%)

109.00M(0.46%)

508.00M(4.35%)

485.00M(4.27%)

510.00M(4.58%)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

United States

International

AMERICAS

Europe,Africa & Middle East (Region)

Asia pacific

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

6.12B(54.45%)

5.85B(55.00%)

5.80B(56.00%)

5.77B(57.36%)

4.94B(40.66%)

--(--)

5.96B(34.93%)

International

5.12B(45.55%)

4.79B(45.00%)

4.56B(44.00%)

4.29B(42.64%)

7.21B(59.34%)

--(--)

AMERICAS

--(--)

6.07B(51.99%)

6.09B(53.63%)

5.95B(34.89%)

Europe,Africa & Middle East (Region)

--(--)

3.13B(26.81%)

2.97B(26.12%)

2.95B(17.27%)

Asia pacific

--(--)

2.48B(21.20%)

2.30B(20.24%)

2.20B(12.91%)